Adjuvant chemotherapy for non-small cell lung cancer.
The survival after complete resection for non-small cell lung cancer (NSCLC) is unsatisfactory. Until recently, the use of adjuvant therapy after resection for early stage disease has not been proven to improve survival. However, the efficacy of adjuvant therapy has been demonstrated in phase III prospective randomized trials. The appropriate use of adjuvant therapy, including biologic therapy, is currently under investigation.
D'Amico
Thomas A
TA
Division of Thoracic Surgery, Duke University Medical Center, Durham, NC 27710, USA. damic001@mc.duke.edu
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use
D000970:Antineoplastic Agents; D015513:Oncogene Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; C507278:survival-related gene product, human; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib